澤璟製藥(688266.SH)首次公開發行6000萬股 網上路演時間13日14:00-17:00
格隆匯1月9日丨澤璟製藥(688266.SH)公佈,公司首次公開發行人民幣普通股(A股)並在科創板上市的申請已於2019年10月30日經上海證券交易所科創板股票上市委員會審議通過,並已經中國證券監督管理委員會同意註冊。
本次發行採用戰略配售、網下發行和網上發行相結合的方式進行。中國國際金融股份有限公司(以下簡稱“中金公司”或“保薦機構(聯席主承銷商)”)擔任本次發行的保薦機構(聯席主承銷商),東吳證券擔任本次發行的聯席主承銷商。
本次擬公開發行股票6000萬股,佔發行後發行人總股本的25.00%。本次發行初始戰略配售數量為300萬股,佔本次發行數量的5.00%,最終戰略配售數量與初始戰略配售數量的差額將首先回撥至網下發行。網下初始發行數量為4560萬股,佔扣除初始戰略配售數量後發行數量的80.00%,網上初始發行數量為1140萬股,佔扣除初始戰略配售數量後發行數量的20.00%。最終網下、網上發行合計數量為本次發行總數量扣除最終戰略配售數量,網上及網下最終發行數量將根據回撥情況確定。
網上路演時間:2020年1月13日(T-1日)14:00-17:00。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.